Revefenacin

Drug Profile

Revefenacin

Alternative Names: GSK 1160724; TD-4208

Latest Information Update: 04 Apr 2017

Price : $50

At a glance

  • Originator Theravance
  • Developer Theravance Biopharma
  • Class Antiasthmatics
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease

Most Recent Events

  • 20 Mar 2017 Theravance Biopharma initiates enrolment in a phase III trial for Chronic obstructive pulmonary disease in USA (NCT03095456)
  • 27 Feb 2017 Theravance plans a phase IIIb trial for Chronic obstructive pulmonary disease
  • 27 Feb 2017 Theravance announces intention to submit NDA to US FDA in late 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top